Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Capital Expenditures: 2022-2025

Historic Capital Expenditures for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to -$171,000.

  • Entrada Therapeutics' Capital Expenditures fell 126.76% to -$171,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 46.18%. This contributed to the annual value of $3.2 million for FY2024, which is 43.75% down from last year.
  • Entrada Therapeutics' Capital Expenditures amounted to -$171,000 in Q3 2025, which was down 162.18% from $275,000 recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Capital Expenditures ranged from a high of $1.7 million in Q1 2023 and a low of -$171,000 during Q3 2025.
  • Its 3-year average for Capital Expenditures is $910,909, with a median of $976,000 in 2023.
  • Its Capital Expenditures has fluctuated over the past 5 years, first soared by 180.81% in 2023, then slumped by 126.76% in 2025.
  • Quarterly analysis of 4 years shows Entrada Therapeutics' Capital Expenditures stood at $708,000 in 2022, then surged by 37.85% to $976,000 in 2023, then slumped by 34.94% to $635,000 in 2024, then tumbled by 126.76% to -$171,000 in 2025.
  • Its last three reported values are -$171,000 in Q3 2025, $275,000 for Q2 2025, and $1.1 million during Q1 2025.